Alembic Pharmaceuticals’ Bioequivalence facility located at Baroda was successfully inspected by US Food & Drug Administration (USFDA) between March 06, 2017 & March 10, 2017, between March 13, 2017 and March 17, 2017 and between April 10, 2017 to April 12, 2017 for Bioequivalence Clinical, Bioequivalence Bioanalytical and Pharmacovigilance. There were no 483s issued by USFDA at the end of the inspection.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
